Company
Headquarters: Taipei, Taiwan
CEO: Mr. Hong-Ren Wang Ph.D.
TW$12.56 Billion
TWD as of Jan. 1, 2025
US$382.6 Million
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $622.07 B |
| Vertex Pharmaceuticals Incorporated | $113.24 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $76.33 B |
| Marinomed Biotech AG | $56.13 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
PharmaEngine, Inc., a biopharmaceutical company, engages in the development and licensing of drugs and therapeutic drugs for treating cancer diseases in Taiwan and Europe. It is developing ONIVYDE for patients with gemcitabine-treated metastatic pancreatic cancer;PEP06, which is in Phase I stage for the treatment of cancer; and PEP07, an oral small molecule drug, which is in preclinical development stage to regulate DNA damage response. PharmaEngine, Inc. was incorporated in 2002 and is headquartered in Taipei, Taiwan.
Top 1-year algo backtest: +327.04%
$10,000 in March 2024 would now be $42,704 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
PharmaEngine, Inc. has the following listings and related stock indices.
Stock: TWSE: 4162 wb_incandescent